BROADOAK SECURES SECOND BIOTECHNOLOGY TENANT FOR MAXIM

 

December 2017

Lamellar Biomedical Limited to occupy two suites

Broadoak Asset Management have secured a second biotechnology tenant and are pleased to announce that innovative biotechnology company Lamellar Biomedical is taking a total of 3,444 sq ft across suites 1 and 5 within the Maxim 1 building on a five-year lease. Fit-out works are now complete ahead of the January 2018 entry date.

The company is developing a range of patent protected medical devices and pharmaceuticals for the healthcare market based on its LAMELLASOME™ technology.  Lamellar plans to use its new premises at Maxim to support the further development of its range of medical devices and pharmaceuticals based upon its unique LAMELLASOME™ technology.

Dr Alec McLean, chief executive officer at Lamellar Biomedical, commented: “We’re thrilled with our new operation at Maxim and are looking forward to relocating to the Park in the New Year”.

“Given the range of partnerships that we have developed with NHS Scotland and leading clinicians and academics across the country, this strategic location within easy reach of major Scottish cities and airports will be hugely beneficial to both the business and our staff. The facilities at Maxim have allowed us to build a state-of-the-art laboratory and office is a contemporary and high-quality facility surrounded by great on-site amenities for our staff, so we are excited about moving in and joining the Maxim community.”

Craig Ritchie, Director at Broadoak Asset Managment, added: “I can confirm with pleasure that Lamellar Biomedical has chosen to relocate to Maxim.  Our strategic location in central Scotland and the flexible nature of the space has meant we’re able to attract and secure companies of such a high calibre.  “Lamellar is the second biotechnology company operating from the Park so it’s fantastic that Maxim is now home to two organisations that are playing a significant role in the Scottish healthcare sector.”  Following the Lamellar deal, and the recent Document Data Group and Europa Logistics announcements, only one small suite, comprising 1,776 sq ft, remains available at Maxim 1.

Lamellar Biomedical joins a growing number of successful organisations operating from the Park including fellow biotechnology company TC BioPharm, SEPA, Wills Bros, Allied Glass, Document Data Group, SureThing, Proact IT, Regus and Balfour Beatty.  Furthermore, Maxim Office Park is situated in the hugely successful Eurocentral which is home to FedEx, Laing O’Rourke and Amazon.